DaVita (DVA)
(Delayed Data from NYSE)
$162.75 USD
-1.18 (-0.72%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $162.74 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$162.75 USD
-1.18 (-0.72%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $162.74 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth F Momentum C VGM
Zacks News
3 Buy Rated Stocks Cruising at 52 Week Highs
by Derek Lewis
Stocks making new highs tend to make even higher highs, particularly when analysts' positive earnings estimate revisions are rolling in.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
by Zacks Equity Research
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $163.08, moving +0.51% from the previous trading session.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
VEEV Stock Down Despite Expansion of Vault QMS to Boost Patient Safety
by Zacks Equity Research
Veeva Systems' addition of new capabilities is likely to improve the timeliness and accuracy of field actions to ensure product quality and patient safety.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $161.57, signifying a -0.01% move from its prior day's close.
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene's Michigan Unit Partners With Mae to Reduce Health Disparities
by Zacks Equity Research
CNC's Meridian unit collaborates with Mae to improve health outcomes and address health disparities in Michigan.
MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout
by Zacks Equity Research
Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio Now
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $163.16, moving -0.65% from the previous trading session.
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
by Zacks Equity Research
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.22, indicating a -0.59% shift from the previous trading day.
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
by Zacks Equity Research
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
by Zacks Equity Research
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
Zacks Investment Ideas feature highlights: Intuitive Surgical, SharkNinja and DaVita
by Zacks Equity Research
Intuitive Surgical, SharkNinja and DaVita have been highlighted in this Investment Ideas article.